SENATE BILL REPORT
SB 6229
This analysis was prepared by non-partisan legislative staff for the use of legislative members in their deliberations. This analysis is not a part of the legislation nor does it constitute a statement of legislative intent. |
As of February 4, 2014
Title: An act relating to good samaritans and life-threatening anaphylaxis.
Brief Description: Concerning use of epinephrine autoinjectors by good samaritans.
Sponsors: Senators Mullet, Rivers, Frockt, Braun, Hewitt, Baumgartner and Keiser.
Brief History:
Committee Activity: Health Care: 2/04/14.
SENATE COMMITTEE ON HEALTH CARE |
Staff: Bonnie Kim (786-7316)
Background: An epinephrine autoinjector is a medical device used to deliver a single dose of epinephrine or adrenaline. Most autoinjectors are spring-loaded syringes used for the treatment of acute allergic reactions to avoid or treat the onset of anaphylactic shock. Anaphylactic shock is a serious allergic reaction with rapid onset and may cause death. Common causes include insect bites or stings, foods, and medications. Common symptoms include an itchy rash, throat swelling, and low blood pressure.
Summary of Bill: A person who uses an epinephrine autoinjector of any brand prescribed by an osteopathic physician or physician during an emergency, and all other persons and entities providing emergency services, are immune from civil liability for any personal injury that results from any act or omission in the use of the autoinjector. This immunity does not apply if the acts or omissions amount to gross negligence or willful or wanton misconduct. The person who uses the epinephrine autoinjector must call 911 or its local equivalent as soon as possible after the emergency use and assure appropriate follow-up information is available if requested by emergency medical services or other health care providers.
Appropriation: None.
Fiscal Note: Not requested.
Committee/Commission/Task Force Created: No.
Effective Date: Ninety days after adjournment of session in which bill is passed.
Staff Summary of Public Testimony: PRO: Eighteen states have passed similar legislation reflecting a recognized best practice among allergy communities.
Persons Testifying: PRO: Senator Mullet, prime sponsor.